MedWatch

Bavarian shows encouraging data for RSV vaccine

Bavarian says a vaccine candidate in its pipeline has shown “broad and durable” immune response against the airway virus RSV.

Foto: Bavarian Nordic

Encouraging phase I data for Bavarian Nordic’s vaccine candidate against respiratory syncytial virus (RSV) shows that the candidate is on the right path, the Danish biotech company said late this week.

The biotech said that 6 month follow-up data from the phase I trial with its candidate MVA-BN RSV shows the antibody response induced by the vaccine candidate remained at similar levels to what had been reported previously. It is proof that MVA-BN RSV induced a durable immune response lasting at least 6 months; a period spanning a normal RSV season, it believes.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier